dapa toto

Introduction. toto situs judi The DAPA-CKD trial showed that the sodium-glucose co-transporter-2 (SGLT2) inhibitor dapagliflozin reduced the relative risk of kidney failure in a broad population of patients with chronic kidney disease with and without type 2 diabetes. rtp kang toto hari ini 1 Drug efficacy estimations using a clinical dichotomous outcome, such as kidney failure, are primarily sensitive to the treatment effect in